Independent fund research. Built on SEC filings.

How we research funds

Mutual fund · Technology Sector · Saratoga Advantage

Health & Biotechnology Portfolio Health & Biotechnology Portfolio Class A (SHPAX)

Ticker SHPAX · · Holdings as of May 31, 2026

Expense ratio
3%$300/yr per $10k
5-yr return
+3.1%annualized
1-yr return
−5.5%as of Dec 2024
Net assets
$10.5Mall share classes
Holdings
29

Bottom line

Is SHPAX a good fund? The bottom line

SHPAX is a share class of Health & Biotechnology Portfolio, a managed technology sector mutual fund from Saratoga Advantage.

Its expense ratio is 3% — about $300 a year on every $10,000 invested, more expensive than 99% of technology sector funds we track.

It returned −5.5% over one year, +3.1% a year over five years, +4.1% a year over ten (as of Dec 31, 2024, per its prospectus).

With $10.5 million in net assets and 29 holdings, its largest position is Cardinal Health Inc (6.4%) and the top 10 make up 50.7% of the portfolio.

This share class carries a front-end sales charge of up to 5.75%; a no-load class or ETF alternative can avoid it.

What to watch

  • Expensive for its category (3%)
  • 5-year return in the bottom quarter of its category
  • Concentrated: top 10 holdings are 50.7% of assets
  • Front-end sales load up to 5.75%
  • Small fund ($10.5 million) — small funds are likelier to close

Updated Nov 19, 2026

What SHPAX invests in

The Health & Biotechnology Portfolio seeks long-term capital growth.

The Portfolio will normally invest at least 80% of its total assets in equity securities of U.S. and foreign healthcare companies and biotechnology companies, regardless of their stock market value (or market capitalization). Equity securities include common stocks, preferred stocks, securities convertible into common stocks and warrants. The Adviser utilizes a top-down investment approach focused on long-term economic trends. The Adviser begins with the overall outlook for the economy, then seeks to identify specific industries with attractive characteristics and long-term growth potential. Ultimately, the Adviser seeks to identify high-quality companies within the selected industries and to acquire them at attractive prices. The Advisers stock selection process is based on an analysis of individual companies fundamental values, such as earnings growth potential and the quality of…

From the fund's prospectus (filed Dec 29, 2025).

SHPAX performance

Fund calendar-year total returns, 2015–2024 2015: +6.9%; 2016: −2.0%; 2017: +12.0%; 2018: −5.5%; 2019: +16.2%; 2020: +3.6%; 2021: +16.7%; 2022: +2.0%; 2023: −0.4%; 2024: +0.3% +7% 2015 −2% 2016 +12% 2017 −5% 2018 +16% 2019 +4% 2020 +17% 2021 +2% 2022 −0% 2023 +0% 2024
Fund gain (+) Fund loss (−)
Average annual total returns
1 yr5 yr10 yr
SHPAX−5.5%+3.1%+4.1%
Technology Sector median+24.0%+10.0%+16.7%

Source: Fund prospectus, as of Dec 31, 2024

Full SHPAX performance history →

What SHPAX costs

On a $10,000 investment, SHPAX's 3% expense ratio costs about $300 a year. The prospectus estimates $3,702 in total costs over 10 years (assuming 5% annual returns). The median technology sector fund charges 0.75%.

See the full SHPAX fee table →

SHPAX top 10 holdings

#Holding% of fund
1Cardinal Health Inc6.44%
2Jazz Pharmaceuticals Plc6.19%
3United Therapeutics Corp6.17%
4Amgen Inc5.04%
5Mckesson Corp4.90%
6Lantheus Holdings Inc4.64%
7Exelixis Inc4.55%
8Novartis Ag4.50%
9Cencora Inc4.33%
10Gilead Sciences Inc3.94%

Source: SEC Form N-PORT, period ended May 31, 2026

The top 10 make up 50.7% of the fund. See all top 25 holdings and asset mix →

Alternatives to SHPAX

More funds like SHPAX →

SHPAX FAQ

What is the expense ratio of SHPAX?
SHPAX's expense ratio is 3%, which works out to about $300 a year for every $10,000 invested. The prospectus estimates total costs of $3,702 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is SHPAX a good investment?
It depends on your goals, but the data points to: expensive for its category (3%); 5-year return in the bottom quarter of its category; concentrated: top 10 holdings are 50.7% of assets; front-end sales load up to 5.75%; small fund ($10.5 million) — small funds are likelier to close. This is general information, not personalized advice.
What does SHPAX hold?
SHPAX's largest holdings are Cardinal Health Inc (6.4%), Jazz Pharmaceuticals Plc (6.2%), United Therapeutics Corp (6.2%), Amgen Inc (5.0%), Mckesson Corp (4.9%). It holds 29 positions in total as of May 31, 2026 (SEC Form N-PORT).
What is SHPAX's 5-year return?
SHPAX returned +3.1% a year over the five years ending Dec 31, 2024, and +4.1% a year over ten years. Past performance does not guarantee future results.
Does SHPAX have a sales load?
Yes. SHPAX has a maximum front-end sales charge of 5.75%.
Who manages SHPAX?
SHPAX is offered by Saratoga Advantage through Saratoga Advantage Trust.